Open Access

Nicotinamide mononucleotide attenuates glucocorticoid‑induced osteogenic inhibition by regulating the SIRT1/PGC‑1α signaling pathway

  • Authors:
    • Rui‑Xiong Huang
    • Jun Tao
  • View Affiliations

  • Published online on: May 4, 2020     https://doi.org/10.3892/mmr.2020.11116
  • Pages: 145-154
  • Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Long-term and high-dose glucocorticoid treatment is recognized as an important influencing factor for osteoporosis and osteonecrosis. Nicotinamide mononucleotide (NMN) is an intermediate of NAD+ biosynthesis, and is widely used to replenish the levels of NAD+. However, the potential role of NMN in glucocorticoid‑induced osteogenic inhibition remains to be demonstrated. In the present study, the protective effects of NMN on dexamethasone (Dex)‑induced osteogenic inhibition, and its underlying mechanisms, were investigated. Bone mesenchymal stem cells were treated with Dex, which decreased the levels of the osteogenic markers alkaline phosphatase, Runt‑related transcription factor 2 and osteocalcin. NMN treatment attenuated Dex‑induced osteogenic inhibition and promoted the expression of sirtuin 1 (SIRT1) and peroxisome proliferator‑activated receptor gamma coactivator (PGC)‑1α. SIRT1 knockdown reversed the protective effects of NMN and reduced the expression levels of PGC‑1α. Collectively, the results of the present study reveal that NMN may be a potential therapeutic target for glucocorticoid‑induced osteoporosis.
View Figures
View References

Related Articles

Journal Cover

July 2020
Volume 22 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Huang, R., & Huang, R. (2020). Nicotinamide mononucleotide attenuates glucocorticoid‑induced osteogenic inhibition by regulating the SIRT1/PGC‑1α signaling pathway. Molecular Medicine Reports, 22, 145-154. https://doi.org/10.3892/mmr.2020.11116
MLA
Huang, R., Tao, J."Nicotinamide mononucleotide attenuates glucocorticoid‑induced osteogenic inhibition by regulating the SIRT1/PGC‑1α signaling pathway". Molecular Medicine Reports 22.1 (2020): 145-154.
Chicago
Huang, R., Tao, J."Nicotinamide mononucleotide attenuates glucocorticoid‑induced osteogenic inhibition by regulating the SIRT1/PGC‑1α signaling pathway". Molecular Medicine Reports 22, no. 1 (2020): 145-154. https://doi.org/10.3892/mmr.2020.11116